Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
With
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The purpose of the study is to understand the effect of lowering serum uric acid levels on vascular function in individuals with chronic kidney disease by comparing the effects of:
1\) Allopurinol therapy and 2) Placebo.
Patients will receive: 3 month study drug (either allopurinol or placebo), with assessment of serum uric acid levels and vascular function.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Individuals with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates between 30-60 mL/min/ 1.73m2
Elevated uric acid levels
Age range: more than 18 years old
Ability to give informed consent
Albumin \> 3.0 g/dL
BMI \< 40 kg/m2
You may not be if
Life expectancy \< 1.0 years
Expected to undergo living related kidney transplant in 6 months
Pregnant, breast feeding, or unwilling to use adequate birth control
History of severe liver disease
History of severe congestive heart failure
History of hospitalizations within 3 months
Active infection, on antibiotics
History of Warfarin Use or other medications that are contraindicated with allopurinol
Uncontrolled hypertension
History of acute gout on Allopurinol
History of adverse reaction to Allopurinol
Immunosuppressive therapy within the last 1 yr
Clareo Health | Uric Acid and the Endothelium in CKD
